BUZZ-获准开始 COVID 抗病毒药物的中期研究,Traws Pharma 受益匪浅

路透中文
Aug 18
BUZZ-获准开始 COVID 抗病毒药物的中期研究,<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> 受益匪浅

8月18日 - ** Traws Pharma TRAW.O股价盘前上涨4%至1.57美元

** TRAW表示,公司已获得人类研究伦理委员会的批准,可以对其COVID-19抗病毒候选药物ratutrelvir进行中期研究。

** 公司预计将在今年年底得出研究结果

** 在一项早期研究中,与辉瑞公司PFE.N的Paxlovid相比,患者每天只需服用一片ratutrelvir,连续服用10天,而辉瑞公司的PFE.NPaxlovid则需要每天服用两次,每次多片,连续服用5天。

** 截至收盘,TRAW股价累计下跌83

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10